MedTrace Logo

Two-channel IV-PCA With Dexmedetomidine

NCT05672225 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 110

Last updated 2025-01-03

No results posted yet for this study

Summary

Dexmedetomidine was administered in the 'selector' channel and fentanyl in the 'basic \& bolus' channel of dual channel intravenous patient-controlled analgesia (IV-PCA) and the amount of opioid consumption was compared. In addition, intensity of pain, postoperative nausea/vomiting, and postoperative delirium was evaluated.

Conditions

  • Analgesia, Patient-Controlled
  • Dexmedetomidine

Interventions

DRUG

Dexmedetomidine

Dexmedetomidine 0.2mcg/kg/hr (2ml/hr) administration via continuous channel in the experimental group

DRUG

Control

Normal saline 2ml/hr administration via continuous channel in the experimental group

Sponsors & Collaborators

  • Korea University Guro Hospital

    lead OTHER

Principal Investigators

  • Seok Kyeong Oh, M.D., Ph.D · Korea University Guro Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-07
Primary Completion
2025-10-31
Completion
2025-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05672225 on ClinicalTrials.gov